Skip to content

SNDX SYNDAX PHARMACEUTICALS INC

Follow

COM (common), issuer CIK 1395937

Filings received so far for Q3 2026: 9 13F filers report a position in SNDX shares at 2026-09-30. The quarter is not complete: its 13F deadline is 2026-11-14, and the counts grow as filings arrive.

13D and 13G filers

No 13D or 13G on this security in the data. Structured 13D/G data starts 2024-12-18.

Insider trades

No Form 4 transaction on this security in the data.

13F holders, Q3 2026

Filers in the available 13F reports with a share position at 2026-09-30, filer groups collapsed to one row (method), largest first. Options and principal amounts are left out. A group row states no % of portfolio, since each member reports its own portfolio: the members' percents are listed under it. A value about 1,000 times or 1/1,000 of the price other filers imply is shown as filed but neither ranks the row nor enters a sum.

HolderSharesValue% of portfolioChangeSource
Hennion & Walsh Asset Management, Inc.386,364$7.26M0.21%+43,48113F-HRTimeline
Harbour Capital Advisors, LLC35,185$661K0.12%+14,53513F-HRTimeline
WEALTH ENHANCEMENT ADVISORY SERVICES, L…20,974$354K<0.01%+1,02413F-HRTimeline
Post Resch Tallon Group Inc.12,300$231K0.16%-20013F-HRTimeline
Versant Capital Management, Inc844$15.9K<0.01%013F-HRTimeline
GAMMA Investing LLC345$6.49K<0.01%-7213F-HRTimeline
Farther Finance Advisors, LLC339$6.37K<0.01%-8713F-HRTimeline
True Wealth Design, LLC242$4.55K<0.01%+1413F-HRTimeline
MassMutual Private Wealth & Trust, FSB71$1.33K<0.01%013F-HRTimeline